


Ending the Epidemic Task Force Recommendation Form

#163



COMPLETE

Collector: Web Link (Web Link)

Started: Wednesday, November 19, 2014 8:17:13 AM

Last Modified: Wednesday, November 19, 2014 8:24:42 AM

Time Spent: 00:07:29

IP Address: 72.0.130.202

PAGE 1

Q1: OPTIONAL: This recommendation was submitted by (please provide your first and last name, affiliation, and email address)

First Name	Valerie
Last Name	Flanders
Affiliation	Albany County Department of Health

Q2: Title of your recommendation PreP & Pep

Q3: Please provide a description of your proposed recommendation

That PreP & Pep be targeted and advertized to women, and made aviable to women. Made aviable to women in reproductive health clinics as well. Make advertizment friendly to women of all ages and races.

Q4: For which goal outlined in the Governor's plan to end the epidemic in New York State does this recommendation apply? (Select all that apply) Facilitating access to Pre-Exposure Prophylaxis (PrEP) for high-risk persons to keep them HIV negative

Q5: This recommendation should be considered by the following Ending the Epidemic Task Force Committee (Select all that apply) Prevention Committee: Develop recommendations for ensuring the effective implementation of biomedical advances in the prevention of HIV, (such as the use of Truvada as pre-exposure prophylaxis (PrEP)); for ensuring access for those most in need to keep them negative; and for expansion of syringe exchange, expanded partner services, and streamlined HIV testing by further implementing the universal offer of HIV testing in primary care, among others. The Committee will focus on continuing innovative and comprehensive prevention and harm reduction services targeted at key high risk populations, as well as grant-funded services that engage in both secondary and primary prevention.

Q6: Does this recommendation require a change to an existing policy or program, or the creation of a new policy or program? Unknown

Ending the Epidemic Task Force Recommendation Form

Q7: Would implementation of this recommendation be permitted under current laws or would a statutory change be required?

Unknown

Q8: Is this recommendation something that could feasibly be implemented in the short-term (within the next year) or long-term (within the next three to six years)?

Unknown

Q9: What are the perceived benefits of implementing this recommendation?

decreasing number of new infections in women

Q10: Are there any concerns with implementing this recommendation that should be considered?

Respondent skipped this question

Q11: What is the estimated cost of implementing this recommendation and how was this estimate calculated?

Respondent skipped this question

Q12: What is the estimated return on investment (ROI) for this recommendation and how was the ROI calculated?

Respondent skipped this question

Q13: Who are the key individuals/stakeholders who would benefit from this recommendation?

Respondent skipped this question

Q14: Are there suggested measures to accompany this recommendation that would assist in monitoring its impact?

Respondent skipped this question

Q15: This recommendation was submitted by one of the following

Respondent skipped this question